Bezac
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Terms and conditions of storage
Bezac is an antiparkinsonian drug.
Release form and composition
The dosage form of Bezac is tablets: flat-cylindrical, round, almost white, with a line and a chamfer (10 or 20 pcs. In blisters, 2, 5 or 10 packs in a cardboard box).
Composition of 1 tablet:
- active substance: biperiden hydrochloride - 2 mg;
- auxiliary components: microcrystalline cellulose - 192 mg, magnesium stearate - 1 mg, sodium carboxymethyl starch - 5 mg.
Indications for use
- parkinson's syndrome;
- extrapyramidal symptoms, including muscle rigidity, tremor, torsion dystonia, local forms of dystonia, incl. paroxysmal dyskinesias, tics of various forms, choreic hyperkinesis, hyperkinesis and myoclonus, dystonia of the muscles of the limbs, face, neck, trunk, akathisia, akinesia associated with the use of antipsychotics or similarly acting drugs.
Contraindications
Absolute:
- hypertrophy of the prostate with urinary retention;
- ileus;
- obstruction or mechanical narrowing of the gastrointestinal tract;
- angle-closure glaucoma;
- age up to 18 years (the safety profile for this group of patients has not been studied);
- lactation period (due to the likely occurrence of anticholinergic effects in a child);
- hypersensitivity to the components of the drug.
Relative (Bezac is prescribed with caution in the presence of the following diseases / conditions):
- arrhythmia;
- myasthenia gravis;
- a tendency to seizures, including anamnestic data;
- hypertrophy of the prostate;
- congestive heart failure;
- cardiac ischemia;
- arterial hypertension;
- ileostomy / colostomy;
- epilepsy;
- pregnancy (due to limited experience of use, the appointment of the drug is possible only after the doctor has assessed the benefit / risk ratio, especially in the first trimester);
- elderly age.
Method of administration and dosage
Bezac is taken orally with a liquid. It is preferable to take the drug at the same time / after meals (allows to reduce the severity of adverse reactions from the digestive system).
Recommended application scheme:
- Parkinson's syndrome: the initial dose is 1–2 times a day, 1 mg. The daily dose can be increased by 2 mg. The maintenance daily dose is 3-16 mg. The maximum is 16 mg per day. The total daily dose must be distributed evenly throughout the day;
- extrapyramidal symptoms (as a corrector for neuroleptic treatment): the initial dose is determined by the severity of symptoms and is 1-2 mg 1-4 times a day. A single dose can be increased to 4 mg, daily - up to 16 mg.
The duration of the course is determined individually, it depends on the etiology and severity of the course of the disease.
After the end of the course, the dose should be reduced gradually (due to the high risk of withdrawal symptoms).
Side effects
In most cases, side effects arise as a result of the anticholinergic action of Bezac.
Possible violations (very often -> 10%; often -> 1% and 0.1% and 0.01% and <0.1%; very rarely - <0.01%):
- cardiovascular system: rarely - lowering blood pressure, tachycardia; very rarely - bradycardia;
- nervous system and sensory organs: motor agitation, anxiety, mydriasis, dizziness, photophobia, fatigue, speech disorders, catalepsy, headache, paresis of accommodation, drowsiness, confusion, memory impairment, angle-closure glaucoma, increased seizure activity, hallucinations, euphoria, disorientation in time and space;
- genitourinary system: rarely - urinary retention;
- digestive system: often - dry mouth; rarely - dyspepsia, constipation, nausea;
- others: rarely - decreased sweating, parotitis, drug dependence, allergic reactions (in the form of a skin rash), muscle twitching, mental disorders.
Except in cases of development of life-threatening complications, abrupt withdrawal of Bezac should be avoided.
special instructions
At the beginning of treatment, it is recommended to increase the dose gradually, which will prevent the occurrence of adverse reactions.
You must not drink alcohol during treatment.
Besac can cause neuromuscular blockage, followed by paralysis and muscle weakness.
In susceptible patients, when anticholinergic drugs are prescribed in recommended therapeutic doses, the development of confusion, euphoria, and motor excitement can be observed.
Elderly patients, especially those with cerebral degenerative / vascular disorders, often develop hypersensitivity to the drug.
Drugs similar in action to Bezak can increase the predisposition to the appearance of epileptic seizures, which must be taken into account when prescribing therapy. Under the influence of biperiden, tardive dyskinesia caused by neuroleptics may increase. In some cases, parkinsonian symptoms that develop against the background of tardive dyskinesia are so severe that they prevent the continuation of the use of anticholinergic drugs.
Abuse of drugs containing biperiden has been noted. This may be due to the improvement in mood and the temporary euphoric effects of these drugs that are sometimes seen.
When dry mouth occurs, symptomatic treatment is indicated and, if necessary, correction of the Bezac dosage regimen.
During long-term treatment, regular monitoring of intraocular pressure should be carried out.
Bezak has a strong effect on psychomotor reactions, and therefore, during the period of treatment, potentially hazardous types of work, the performance of which requires rapid motor and mental reactions, must be abandoned. Carrying out therapy, especially in combination with anticholinergic drugs and other drugs of central action, can lead to impairment of the ability to work with mechanisms and drive vehicles.
Drug interactions
With the combined use of Bezac with certain drugs / substances, the following effects may develop:
- ethanol: potentiating its action;
- antipsychotics: an increase in the likelihood of tardive dyskinesia;
- anticholinergic drugs: increased peripheral and central anticholinergic effects;
- quinidine: an increase in the likelihood of dyskinesia (associated with an increase in anticholinergic effects);
- levodopa: increased dyskinesia and m-anticholinergic action;
- blockers of histamine III-receptors, anticonvulsants: enhancing their action;
- metoclopramide: decrease in its effectiveness.
Terms and conditions of storage
Store in a dark place, out of reach of children, at temperatures up to 30 ° C.
The shelf life is 3 years.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
